AVROBIO INC (AVRO)

Company Profile

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 78 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The firm is focusing on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies. Its pipeline is comprised of various HSC gene therapy programs, which include AVR-RD-02 for the treatment of Gaucher disease type 1 and type 3; AVR-RD-05 for the treatment of neuronopathic mucopolysaccharidosis type II (MPS-II) or Hunter syndrome; and AVR-RD-03 for the treatment of Pompe disease.

Company Info

AVROBIO INC

100 Technology Square, 6th Floor

Cambridge MASSACHUSETTS 02139

P: 16179148420

CEO: Geoff MacKay

Employees: 78

Website: https://www.avrobio.com/